Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689261 | 1.00 | PTGER2 (0.59) | PTGER2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL689403 | 0.89 | PTGER2 (0.60) | PTGER2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL27867877 | 0.89 | PTGER2 (0.57) | PTGER2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL10056655 | 0.89 | SMN1; SMN2 (0.50) | PTGER2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL689268 | 0.86 | PTGER2 (0.55) | PTGER2MAPTKDM4E | |
| SCHEMBL6152201 | 0.86 | PTGER2 (0.54) | PTGER2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1567586 | 0.84 | PTGER2 (0.53) | PTGER2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL13083610 | 0.83 | GPR84 (0.54) | PTGER2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1566041 | 0.82 | PTGER2 (0.68) | PTGER2HDAC3HDAC1HDAC2 | |
| SCHEMBL10024677 | 0.82 | HDAC3 (0.46) | PTGER2HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038545-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | Universidad Del País Vasco (ES) | 2015-02-05 | — | — | US | disclosed |
| US-20150038545-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | Universidad Del País Vasco (ES) | 2015-02-05 | — | — | US | disclosed |
| US-20150038545-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | Universidad Del País Vasco (ES) | 2015-02-05 | — | — | US | disclosed |
| EP-2694475-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | Ikerchem, S.L. (ES) | 2014-02-12 | — | — | EP | disclosed |
| EP-2483242-B1 | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers | IKERCHEM S L (ES) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012136722-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | IKERCHEM, S.L. (ES) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012136722-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | IKERCHEM, S.L. (ES) | 2012-10-11 | — | — | WO | disclosed |
| EP-2508510-A1 | Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof | Ikerchem, S.L. (ES) | 2012-10-10 | — | — | EP | disclosed |
| EP-2508510-A1 | Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof | Ikerchem, S.L. (ES) | 2012-10-10 | — | — | EP | disclosed |
| CN-102648177-A | New histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers | IKERCHEM S L | 2012-08-22 | — | — | CN | disclosed |
| EP-2305643-A1 | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers | Ikerchem, S.L. (ES) | 2011-04-06 | — | — | EP | disclosed |
| US-7638550-B2 | new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases. | Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) (ES) | 2009-12-29 | — | — | US | disclosed |
| US-7638550-B2 | new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases. | Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) (ES) | 2009-12-29 | — | — | US | disclosed |
| US-7638550-B2 | new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases. | Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) (ES) | 2009-12-29 | — | — | US | disclosed |
| US-20080262073-A1 | Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (CNIO) (ES) | 2008-10-23 | — | — | US | disclosed |
| US-20080262073-A1 | Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (CNIO) (ES) | 2008-10-23 | — | — | US | disclosed |
| US-20080262073-A1 | Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (CNIO) (ES) | 2008-10-23 | — | — | US | disclosed |
| EP-1975158-A1 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO UNIBERSITATEA (ES) | 2008-10-01 | — | — | EP | disclosed |
| EP-1975158-A1 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO UNIBERSITATEA (ES) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007074176-A1 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIVERSIDAD DEL PAIS VASCO - EUSKAL HERRIKO UNIBERTSITATEA (UPV-EHU) (ES) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262073-A1 | Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity | HDAC1, HDAC11, HDAC5 | PTGER2 3332/4885HDAC3 8/4885HDAC1 1/4885 |
| US-20150038545-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | HDAC1, HDAC5, HDAC2 | PTGER2 2574/4885HDAC3 8/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.